Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach.
Fiche publication
Date publication
mars 2023
Journal
Rheumatology (Oxford, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène, Pr GOTTENBERG Jacques-Eric
Tous les auteurs :
Felten R, Ye T, Schleiss C, Schwikowski B, Sibilia J, Monneaux F, Dumortier H, Jonsson R, Lessard C, Ng F, Takeuchi T, Mariette X, Gottenberg JE
Lien Pubmed
Résumé
To date, no immunomodulatory drug has demonstrated its efficacy in primary Sjögren's syndrome (pSS). We sought to analyze potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes.
Mots clés
Clue, Drug repurposing, Histone deacetylase inhibitors, Interferons, Sjögren’s syndrome, Therapeutics, Transcriptomic signature
Référence
Rheumatology (Oxford). 2023 03 3;: